Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (51-60 of 141) with videos related to

Pageof 15
Sort By:
Nuclear Medicine Communications|March 15, 2006
Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis?Kathrin Marx, Detlef Moka, Klaus Schomäcker, et al.
Hemasphere|November 15, 2019
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions UnansweredPeter Borchmann, Alexander Fosså, Monika Długosz-Danecka, et al.
Molecules (Basel, Switzerland)|January 11, 2024
From Bench to Bedside: Patient-Oriented Radiopharmaceutical Development in Nuclear Medicine Based on the Example of [<sup>89</sup>Zr]Zr-PSMA-DFOKlaus Schomäcker, Felix Dietlein, Sergio Muñoz Vázquez, et al.
EJNMMI Research|September 21, 2023
Threshold for defining PSMA-positivity prior to <sup>177</sup>Lu-PSMA therapy: a comparison of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]F-DCFPyL in metastatic prostate cancerJan Heilinger, Jasmin Weindler, Katrin Sabine Roth, et al.
Clinical Endocrinology|August 23, 2011
Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapyDeniz Kahraman, Christian Keller, Christina Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison studyBoris Decarolis, Christina Schneider, Barbara Hero, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 18, 2015
Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysisGeorg Kuhnert, Ronald Boellaard, Sergej Sterzer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupJustin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate CancerSteven P Rowe, Alexander Drzezga, Bernd Neumaier, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2012
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PETMatthias Scheffler, Carsten Kobe, Thomas Zander, et al.
Pageof 15

Showing results (51-60 of 141) with videos related to

Sort By:
Pageof 15
Nuclear Medicine Communications|March 15, 2006
Cell death induced by 131 I in a differentiated thyroid carcinoma cell line in vitro: necrosis or apoptosis?Kathrin Marx, Detlef Moka, Klaus Schomäcker, et al.
Hemasphere|November 15, 2019
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions UnansweredPeter Borchmann, Alexander Fosså, Monika Długosz-Danecka, et al.
Molecules (Basel, Switzerland)|January 11, 2024
From Bench to Bedside: Patient-Oriented Radiopharmaceutical Development in Nuclear Medicine Based on the Example of [<sup>89</sup>Zr]Zr-PSMA-DFOKlaus Schomäcker, Felix Dietlein, Sergio Muñoz Vázquez, et al.
EJNMMI Research|September 21, 2023
Threshold for defining PSMA-positivity prior to <sup>177</sup>Lu-PSMA therapy: a comparison of [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]F-DCFPyL in metastatic prostate cancerJan Heilinger, Jasmin Weindler, Katrin Sabine Roth, et al.
Clinical Endocrinology|August 23, 2011
Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapyDeniz Kahraman, Christian Keller, Christina Schneider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison studyBoris Decarolis, Christina Schneider, Barbara Hero, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 18, 2015
Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysisGeorg Kuhnert, Ronald Boellaard, Sergej Sterzer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupJustin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate CancerSteven P Rowe, Alexander Drzezga, Bernd Neumaier, et al.
Lung Cancer (Amsterdam, Netherlands)|June 26, 2012
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PETMatthias Scheffler, Carsten Kobe, Thomas Zander, et al.
Pageof 15